drugset / Trial / NCT05710198

Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma

NCT05710198

Phase 3 Recruiting 1000 enrolled Omikron Italia S.r.l. OPIS Spain · collab
RandomizedParallel-groupQuadruple-blindPrevention

Summary

To evaluate the efficacy of citicoline eye drops 2% in reducing visual field deterioration in patients with progressing OAG treated according to best clinical practice. Secondary objectives are assessing the effect of citicoline eye drops 2% on changes in structural parameters measured by Spectral Domain Optical Coherence Tomography (SD-OCT) and evaluating the safety of citicoline eye drops 2%

Timeline

Start
2023-12-11
Primary completion
2026-04-01
Completion
2027-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Citicoline Other / unclassified 2 % Topical

Indications